SCHEMBL4019220

SCHEMBL4019220

CN(C)C(=O)CN1CC(C(=O)c2ccccc2)C(c2ccccc2Cl)C(C(=O)c2ccccc2)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.39
DRD4 P21917 1/20 0.38
KDM4E B2RXH2 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KCNH2 Q12809 1/20 0.37
FFAR2 O15552 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36
HTR6 P50406 1/20 0.35
PDE5A O76074 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019216 1.00 RORC (0.39) RORCDRD4KDM4ENPSR1MEN1
SCHEMBL4021412 0.91 RORC (0.36) RORCDRD4NPSR1MEN1KMT2A
SCHEMBL4021408 0.91 RORC (0.36) RORCDRD4NPSR1MEN1KMT2A
SCHEMBL4019050 0.89 KMT2A (0.41) RORCDRD4MEN1KMT2ACYP1A2
SCHEMBL4022230 0.89 KMT2A (0.48) RORCDRD4MEN1KMT2ACYP1A2
SCHEMBL4019043 0.89 KMT2A (0.41) RORCDRD4MEN1KMT2ACYP1A2
SCHEMBL4022233 0.89 KMT2A (0.48) RORCDRD4MEN1KMT2ACYP1A2
SCHEMBL4025031 0.87 LMNA (0.37) RORCDRD4KDM4ENPSR1MEN1
SCHEMBL4026443 0.87 TERT (0.40) RORCNPSR1MEN1KMT2AKCNH2
SCHEMBL4026439 0.87 TERT (0.40) RORCNPSR1MEN1KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 RORC 183/4885DRD4 2983/4885KDM4E 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.